Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat

Source: ET Real Estate
Arth Insight · What this means for your wallet
- The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
- Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
- The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
- ▸The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
- ▸Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
- ▸The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
- ▸Improved patient follow-up and monitoring of complications are also key aspects being addressed.
- ✓The Cabinet Secretariat has ordered the Health Ministry to investigate coronary stent safety issues.
- ✓Concerns were raised by MP Ajeet Madhavrao Gopchade, citing models withdrawn in Sri Lanka.
- ✓The directive emphasizes strengthening regulatory frameworks, clinical documentation, and device traceability.
- ✓Improved patient follow-up and monitoring of complications are also key aspects being addressed.
In a significant move aimed at enhancing patient safety and medical device regulation, the Cabinet Secretariat has instructed the Union Health Ministry to conduct a thorough examination of safety issues related to coronary stents. This directive comes in response to specific concerns articulated by Rajya Sabha member Ajeet Madhavrao Gopchade.
MP Raises Alarm Over Stent Safety
Mr. Gopchade drew attention to particular coronary stent models that have reportedly been withdrawn from the market in Sri Lanka due to safety issues. His representation to the authorities underscored the urgent need for India to bolster its existing regulatory framework governing these critical medical devices. Coronary stents are small, expandable tubes used to open narrowed or blocked arteries in the heart, a common procedure for patients suffering from coronary artery disease.
Key Demands for Regulatory Improvement
During his address, the Rajya Sabha member outlined several crucial areas requiring immediate attention to safeguard patient well-being. These include:
- Strengthening India's Regulatory Framework: A robust regulatory system is vital to ensure that all medical devices, especially high-risk ones like coronary stents, meet stringent safety and quality standards before and after they are used in patients. This could involve more rigorous testing, clearer approval processes, and stricter post-market surveillance.
- Improved Clinical Documentation: Better record-keeping of clinical procedures involving stent implantation is essential. Comprehensive documentation helps track the device's performance, patient outcomes, and any complications that may arise, allowing for faster identification of issues.
- Robust Traceability for Implanted Stents: Establishing a strong system to trace every implanted stent from its manufacturing point to the specific patient allows for swift recalls if a batch is found to be faulty. It also ensures accountability and facilitates targeted patient follow-ups.
- Importance of Patient Follow-up: Regular monitoring of patients who have received stent implants is critical. This ensures that any device-related complications are detected early and managed effectively, improving long-term patient health.
- Monitoring of Device-Related Complications: A systematic approach to track and analyze all complications linked to coronary stents is necessary. This data is invaluable for identifying trends, improving device design, and refining clinical practices.
What This Means for Patients
The Cabinet Secretariat's directive signals a serious commitment from the government to address public health concerns regarding medical devices. For Indian retail readers and patients, this could translate into greater confidence in the safety and quality of coronary stents used in the country. A more rigorous regulatory environment, coupled with better traceability and patient follow-up, has the potential to significantly enhance patient safety and outcomes for a procedure that affects thousands of lives annually.
The Union Health Ministry's examination is expected to delve into the specifics of the concerns raised and propose concrete measures to strengthen the oversight and safety protocols for coronary stents across India.
This report is for informational purposes only and does not constitute medical or investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Why has the Union Health Ministry been asked to examine coronary stent safety?
The Cabinet Secretariat directed the ministry to investigate safety issues after Rajya Sabha member Ajeet Madhavrao Gopchade highlighted concerns, particularly regarding certain stent models withdrawn in Sri Lanka.
What specific improvements is the government looking to implement for coronary stents?
The government aims to strengthen India's regulatory framework for coronary stents, improve clinical documentation, establish robust traceability for implanted stents, enhance patient follow-up, and better monitor device-related complications.
Who raised the initial concerns about coronary stent safety in India?
Rajya Sabha member Ajeet Madhavrao Gopchade brought these safety concerns to the attention of the authorities, leading to the Cabinet Secretariat's directive.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.
BreakingBR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.
Related Stories

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.
BreakingBR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.
BreakingGovernment Panel Finalises 30% Trade Margin Cap on Cancer Drugs; ₹2,500 Crore Annual Savings Expected
An expert group is finalizing a list of cancer medicines that will be subject to a new 30% trade margin cap. This government initiative aims to significantly reduce the cost of anti-cancer drugs, potentially saving Indian patients ₹2,500 crore annually and leading to retail price drops of up to 70% on some medicines.